Allergan Adds Device To Glaucoma Portfolio
This article was originally published in The Gray Sheet
Executive Summary
The pharmaceutical firm is entering the highly touted micro-invasive glaucoma surgery space with an acquisition of AqueSys, adding a device to its established portfolio of glaucoma drugs.